PharVision Advisers’s NOV NOV Stock Holding History

PharVision Advisers’s Portfolio NOV Stock Details NOV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-11,416	Closed	-$178K	–	468
2025 Q4	$178K	Buy	+11,416	New	+$169K	0.09%	592
2025 Q2	–	Sell	-10,708	Closed	-$163K	–	375
2025 Q1	$163K	Buy	+10,708	New	+$160K	0.23%	222

Other funds holding NOV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Pzena Investment Management New York $30.8B AUM 11.29% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

PharVision Advisers's NOV Position: Q1 2026 in Review

PharVision Advisers sold out of NOV (NOV) in Q1 2026, closing a stake of 11,416 shares — an estimated $178K sold.

PharVision Advisers first reported a position in NOV in Q1 2025 and held it in 2 quarters. The position peaked at $178K in Q4 2025. 464 funds tracked by Wall St. Rank hold NOV as of Q1 2026.

PharVision Advisers reported no remaining NOV position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 11,416 NOV shares in Q1 2026, an estimated $178K.
PharVision Advisers first reported a position in NOV in Q1 2025 and held it in 2 quarters.
PharVision Advisers's NOV position peaked at $178K in Q4 2025.
464 funds tracked by Wall St. Rank held NOV as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.